Form 4: Invivyd CHRO Sells Shares for Tax Obligations

Invivyd's Chief Human Resources Officer, Julie Green, sold shares to cover tax obligations following the vesting of Restricted Stock Units.

Summary

• Julie Green, Chief Human Resources Officer of Invivyd, Inc. (IVVD), acquired 99,000 shares of common stock on August 15, 2025, through the vesting of Restricted Stock Units (RSUs).
• These RSUs represent a contingent right to receive one share of common stock per unit.
• On August 18, 2025, Green sold 20,013 shares at a weighted average price of $0.6502 per share, with prices ranging from $0.5801 to $0.7134.
• On August 19, 2025, an additional 29,643 shares were sold at a weighted average price of $0.5666 per share, with prices ranging from $0.5524 to $0.6040.
• The sales were non-discretionary 'sell-to-cover' transactions executed under a Rule 10b5-1 plan adopted on February 20, 2025, to satisfy tax withholding obligations.
• Following these transactions, Julie Green directly beneficially owns 49,344 shares of common stock and 201,000 Restricted Stock Units.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there is insider selling, it is explicitly stated as non-discretionary 'sell-to-cover' for tax purposes under a pre-arranged plan, which is a routine event and generally not viewed negatively. The vesting of RSUs indicates continued executive compensation and retention.

Positives

• The vesting of 99,000 Restricted Stock Units indicates continued compensation and retention of a key executive, the Chief Human Resources Officer.
• The sales were conducted under a pre-arranged Rule 10b5-1 plan, indicating they were non-discretionary and not based on new material non-public information.

Negatives

• The sale of 49,656 shares by a key executive, even for tax purposes, represents a reduction in insider ownership.

Risks

• The weighted average sale prices of $0.6502 and $0.5666 indicate a low share price, which could reflect underlying company performance or market sentiment.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic outlook. It focuses solely on past insider transactions.

Management Comments

• The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary 'sell-to-cover' transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025.

Industry Context

This Form 4 filing details a routine insider transaction (RSU vesting and sell-to-cover) for a Chief Human Resources Officer. Such transactions are common across all industries for executives receiving equity compensation and do not inherently reflect broader industry trends or competitive positioning.

Comparison to Industry Standards

• The use of a Rule 10b5-1 plan for 'sell-to-cover' transactions is a standard practice among executives in publicly traded companies across various sectors, including biotechnology and pharmaceuticals, to manage tax liabilities associated with equity compensation while adhering to insider trading regulations. This practice is consistent with corporate governance best practices observed in companies like Moderna (MRNA) or Pfizer (PFE) where executives frequently utilize such plans for similar purposes.
• The vesting schedule of one-third of RSUs every six months over an eighteen-month period is a common equity compensation structure designed to incentivize long-term executive retention and performance, comparable to vesting schedules seen at other biotech firms.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale of shares by an executive, even for tax purposes, slightly dilutes insider ownership, but the pre-planned nature mitigates concerns about opportunistic selling. The continued vesting of RSUs indicates ongoing alignment of executive interests with shareholder value.
• Employees: The RSU vesting and compensation structure reflect standard practices for executive incentives, which can positively influence employee morale and retention strategies.

Next Steps

• Future vesting events for the remaining 201,000 Restricted Stock Units will occur every six months following February 15, 2025, subject to continuous service.

Key Dates

Keywords

Invivyd, IVVD, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Sell-to-Cover, Rule 10b5-1 Plan, Executive Compensation, Julie Green